A031501

Pembrolizumab in Treating Patients With Locally Advanced Bladder Cancer. Click here to learn more.

CA209-901

A Phase 3, Open-label, Randomized Study of Nivolumab Combined With Ipilimumab, or With Standard of Care Chemotherapy, Versus Standard of Care Chemotherapy in Participants With Previously Untreated Unresectable or Metastatic Urothelial Cancer. Click here to learn more.

DZB-CS-201

Derazantinib and Atezolizumab in Patients With Urothelial Cancer (FIDES-02). Click here to learn more.

NORSE

A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer. Click here to learn more.

THOR

A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations. Click here to learn more.

 


Learn more about Bladder Cancer >

Our Affiliations

 

 QCCA The Cancer FoundationNCI

We’re Here to Help! Click Below to Get Started

Contact Us Now